• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

一项关于肾衰竭患者经皮腔内肾血管成形术疗效的研究。

A study on the outcome of percutaneous transluminal renal angioplasty in patients with renal failure.

作者信息

Roussos Louis, Christensson Anders, Thompson Olof

机构信息

Department of Nephrology and Transplantation, Malmö University Hospital, Malmö, Sweden.

出版信息

Nephron Clin Pract. 2006;104(3):c132-42. doi: 10.1159/000094916. Epub 2006 Aug 7.

DOI:10.1159/000094916
PMID:16899992
Abstract

BACKGROUND

The indications for percutaneous transluminal renal angioplasty (PTRA) in renovascular disease, as well as its benefits, remain a matter of debate. The aim of this study was to evaluate the outcome of angioplasty and to identify risk factors associated with less successful outcomes in patients with atheromatous renal artery stenosis and renal failure of varying degrees.

METHODS

The results of PTRA were analyzed retrospectively in 144 patients with serum creatinine levels of >130 micromol/l. Patients were divided into 5 groups according to their indication for angioplasty: (1) deteriorating renal function; (2) accelerating hypertension; (3) a combination of 1 and 2; (4) peripheral vascular disease, and (5) miscellaneous conditions.

RESULTS

The baseline mean (+/- SD) systolic and diastolic blood pressures of the entire group were lowered from 180 +/- 32 and 95 +/- 16 mm Hg to 162 +/- 23 and 86 +/- 12 mm Hg, respectively (p < 0.0005), 12 months after angioplasty. The blood pressure level was unaffected by angioplasty in patients with claudication. The mean number of antihypertensive drugs was reduced in the group with accelerating hypertension from 2.9 +/- 0.8 to 2.4 +/- 1.2 (p = 0.019), and in the group with unilateral renal artery stenosis and two kidneys from 2.4 +/- 1.0 to 1.8 +/- 1.1 (p = 0.002), 12 months after PTRA. Glomerular filtration rate at 3-month follow-up had increased from 23 +/- 11 to 27 +/- 14 ml/min/1.73 m(2) (p = 0.021) in group 1, from 25 +/- 11 to 28 +/- 14 ml/min/1.73 m(2) (p = 0.031) in the combined group of patients consisting of groups 1 and 3, and from 32 +/- 13 to 35 +/- 14 ml/min/1.73 m(2) (p = 0.019) in the group with unilateral renal artery stenosis. No statistically significant difference was found in any of these 3 groups 1 year after angioplasty. The first patient group had an increased prevalence of cardiovascular disease, aortic aneurysm, carotid occlusive disease, and peripheral vascular disease compared to the other patient groups (p < 0.05). Patients with baseline creatinine levels of >300 micromol/l had a lower survival rate at 12, 60, and 120 months after PTRA than patients with serum creatinine levels of <300 micromol/l (p < 0.005). Survival was also lower in patients with bilateral renal artery stenosis and those with a single kidney, compared to patients with a unilateral stenosis at both 5 and 10 years after PTRA (p < 0.05). Regression analysis of predictor variables of mortality rate showed that the relative risk (RR) associated with increased serum creatinine was 4.7 (CI 2.0-11.0; p < 0.0005). The RR for older patients was 1.1 (CI 1.0-1.2; p = 0.008), and the RR for former smokers was 6.0 (CI 1.6-24.0; p = 0.009).

CONCLUSION

The results of the present study indicate that glomerular filtration can be improved in patients who primarily undergo angioplasty to rescue renal function. Renal function with creatinine levels of >300 micromol/l was associated with a lower survival rate. It is, therefore, possible that patients selected after a thorough evaluation of their renal function and comorbid disease factors may benefit from PTRA, even when the indication for angioplasty is to salvage renal function.

摘要

背景

经皮腔内肾血管成形术(PTRA)在肾血管疾病中的适应证及其益处仍存在争议。本研究的目的是评估血管成形术的结果,并确定不同程度动脉粥样硬化性肾动脉狭窄和肾衰竭患者中与预后不佳相关的危险因素。

方法

回顾性分析144例血清肌酐水平>130微摩尔/升患者的PTRA结果。根据血管成形术的适应证将患者分为5组:(1)肾功能恶化;(2)高血压加速;(3)1和2的组合;(4)周围血管疾病,以及(5)其他情况。

结果

血管成形术后12个月,整个组的基线平均(±标准差)收缩压和舒张压分别从180±32和95±16毫米汞柱降至162±23和86±12毫米汞柱(p<0.0005)。间歇性跛行患者的血压水平不受血管成形术影响。高血压加速组的抗高血压药物平均数量从2.9±0.8减少到2.4±1.2(p = 0.019),单侧肾动脉狭窄和双肾组从2.4±1.0减少到1.8±1.1(p = 0.002),PTRA术后12个月。随访3个月时,第1组的肾小球滤过率从23±11增加到27±14毫升/分钟/1.73平方米(p = 0.021),第1组和第3组合并组的患者从25±11增加到28±14毫升/分钟/1.73平方米(p = 0.031),单侧肾动脉狭窄组从32±13增加到35±14毫升/分钟/1.73平方米(p = 0.019)。血管成形术后1年,这3组中均未发现统计学上的显著差异。与其他患者组相比,第一组患者心血管疾病、主动脉瘤、颈动脉闭塞性疾病和周围血管疾病的患病率更高(p<0.05)。基线肌酐水平>300微摩尔/升的患者在PTRA术后12、60和120个月的生存率低于血清肌酐水平<300微摩尔/升的患者(p<0.005)。与单侧狭窄患者相比,双侧肾动脉狭窄患者和单肾患者在PTRA术后5年和10年的生存率也较低(p<0.05)。死亡率预测变量的回归分析表明,血清肌酐升高相关的相对风险(RR)为4.7(CI 2.0 - 11.0;p<0.0005)。老年患者的RR为1.1(CI 1.0 - 1.2;p = 0.008),既往吸烟者的RR为6.0(CI 1.6 - 24.0;p = 0.009)。

结论

本研究结果表明,对于主要接受血管成形术以挽救肾功能的患者,肾小球滤过功能可得到改善。肌酐水平>300微摩尔/升的肾功能与较低的生存率相关。因此,即使血管成形术的适应证是挽救肾功能,在对肾功能和合并疾病因素进行全面评估后选择的患者也可能从PTRA中获益。

相似文献

1
A study on the outcome of percutaneous transluminal renal angioplasty in patients with renal failure.一项关于肾衰竭患者经皮腔内肾血管成形术疗效的研究。
Nephron Clin Pract. 2006;104(3):c132-42. doi: 10.1159/000094916. Epub 2006 Aug 7.
2
Predictors of long-term beneficial effects on blood pressure after percutaneous transluminal renal angioplasty in atherosclerotic renal artery stenosis.经皮腔内肾血管成形术治疗动脉粥样硬化性肾动脉狭窄后血压长期有益影响的预测因素。
Int Angiol. 2009 Apr;28(2):106-12.
3
Comparison of early and long-term impact of percutaneous transluminal renal artery angioplasty alone or with brachytherapy on renal function in patients with reno-vascular hypertension.经皮腔内肾动脉血管成形术单独或联合近距离放射治疗对肾血管性高血压患者肾功能的早期和长期影响比较
Kardiol Pol. 2008 Oct;66(10):1061-6; discussion 1067-8.
4
Revascularisation of renal artery stenosis caused by fibromuscular dysplasia: effects on blood pressure during 7-year follow-up are influenced by duration of hypertension and branch artery stenosis.纤维肌性发育异常所致肾动脉狭窄的血管重建:7年随访期间对血压的影响受高血压病程和分支动脉狭窄的影响。
J Hum Hypertens. 2005 Oct;19(10):761-7. doi: 10.1038/sj.jhh.1001893.
5
Does percutaneous transluminal renal artery angioplasty improve blood pressure control and renal function in patients with atherosclerotic renal artery stenosis?经皮腔内肾动脉血管成形术能否改善动脉粥样硬化性肾动脉狭窄患者的血压控制和肾功能?
Isr Med Assoc J. 2011 Oct;13(10):619-24.
6
Prospective randomized trial of operative vs interventional treatment for renal artery ostial occlusive disease (RAOOD).肾动脉开口闭塞性疾病(RAOOD)手术治疗与介入治疗的前瞻性随机试验。
J Vasc Surg. 2009 Mar;49(3):667-74; discussion 674-5. doi: 10.1016/j.jvs.2008.10.006. Epub 2009 Jan 9.
7
Percutaneous transluminal renal angioplasty with stent is effective for blood pressure control and renal function improvement in atherosclerotic renal artery stenosis patients.经皮腔内肾血管成形术伴支架置入术治疗肾动脉粥样硬化性狭窄患者的血压控制和肾功能改善有效。
Chin Med J (Engl). 2012 Apr;125(8):1363-8.
8
Endovascular management of atherosclerotic renovascular disease: early results following primary intervention.动脉粥样硬化性肾血管疾病的血管内治疗:初次干预后的早期结果
J Vasc Surg. 2008 Sep;48(3):580-7; discussion 587-8. doi: 10.1016/j.jvs.2008.04.050.
9
Which patients with hypertension and atherosclerotic renal artery stenosis benefit from immediate intervention?哪些患有高血压和动脉粥样硬化性肾动脉狭窄的患者能从即刻干预中获益?
J Hum Hypertens. 2004 Feb;18(2):91-6. doi: 10.1038/sj.jhh.1001641.
10
Renal artery revascularization improves heart failure control in patients with atherosclerotic renal artery stenosis.肾动脉血运重建可改善粥样硬化性肾动脉狭窄患者的心衰控制。
Nephrol Dial Transplant. 2010 Mar;25(3):813-20. doi: 10.1093/ndt/gfp393. Epub 2009 Aug 7.

引用本文的文献

1
Predictors of complications and extended length of stay following percutaneous transluminal renal artery angioplasty.经皮腔内肾动脉血管成形术后并发症及延长住院时间的预测因素。
Medicine (Baltimore). 2024 Dec 27;103(52):e41017. doi: 10.1097/MD.0000000000041017.
2
Atherosclerotic renovascular disease and renal impairment: can we predict the effect of intervention?动脉粥样硬化性肾血管疾病与肾功能损害:我们能否预测干预效果?
Curr Hypertens Rep. 2007 Apr;9(2):140-7. doi: 10.1007/s11906-007-0025-3.